Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India-Reference-Cited by-同舟云学术

Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India

Published:2008-06 Issue:2 Volume:62 Page:196-213
ISSN:1035-7718
Container-title:Australian Journal of International Affairs
language:en
Short-container-title:Australian Journal of International Affairs

Author:

Faunce Thomas,Shats Kathy

Publisher

Informa UK Limited

Subject

Political Science and International Relations,Geography, Planning and Development

Link

http://www.tandfonline.com/doi/pdf/10.1080/10357710802060550

Reference47 articles.

1. Abbott , T. , 2006 . Press Conference – PBS reform , Commonwealth Parliamentary Offices, Sydney 16 November 2006, (accessed 1 September 2007) .

2. Australian Government Productivity Commission , 2001 . ‘International Pharmaceutical Price Differences Research Report’ p6 , (accessed 1 September 2007) .

3. Australian Department of Foreign Affairs and Trade (DFAT) , 2007 . ‘Australia-China Free Trade Agreement Negotiations’ , (accessed 1 September 2007) .

4. Australian Department of Industry, Tourism and Resources (DITR) , 2007 . ‘Pharmaceuticals Industry Profile’ , (accessed 1 September 2007) .

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Australia's embrace of investor state dispute settlement: a challenge to the social contract ideal?;Australian Journal of International Affairs;2015-07-07

2. The Governance of Patents and Pharmaceuticals: The Regional FTA Contribution;MPI Studies on Intellectual Property and Competition Law;2014-11-05

3. Introduction;Patently Innovative;2012

4. The Trans‐Pacific Partnership Agreement: challenges for Australian health and medicine policies;Medical Journal of Australia;2011-01

5. Evaluation of policies to support drug development in New Zealand;Health Policy;2010-07